Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887536 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase 3 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,613
- Enrollment target
NCT00887536 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 1,613 participants.
The verdict
NCT00887536, a Phase 3 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,613 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.
Interventions
- DRUG cyclophosphamide
- DRUG bevacizumab
- DRUG docetaxel
- DRUG pegfilgrastim
- DRUG doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,613 participants |
| Start Date | 2009-05 |
| Est. Completion | 2018-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887536
The ClinicalTrials.gov registry entry for NCT00887536 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00887536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00887536 about?
NCT00887536 is a clinical study titled "A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer". The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizu...
What is the current status of trial NCT00887536?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,613 participants. The study started on 2009-05. Estimated completion is 2018-02.
What interventions are being tested in trial NCT00887536?
The interventions under investigation include: cyclophosphamide (DRUG), bevacizumab (DRUG), docetaxel (DRUG), pegfilgrastim (DRUG), doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00887536?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.